BACKGROUND: Most non-small cell lung cancers (NSCLC) are chemoresistant. Identification and modulation of chemoresistance cell-signaling pathways may sensitize NSCLC to chemotherapy and improve patient outcome. The purpose of this study was to determine if chemotherapy induces nuclear factor-kappa B (NF-kappaB) activation in NSCLC in vitro and whether inhibition of NF-kappaB would sensitize tumor cells to undergo chemotherapy-induced apoptosis. METHODS: Non-small cell lung cancer cells were treated with gemcitabine, harvested, and nuclear extracts analyzed for NF-kappaB DNA binding by electrophoretic mobility shift assays. Additionally, NSCLC cells that stably expressed a plasmid encoding the superrepressor IkappaBalpha protein (H157I) or a vector control (H157V) were generated. These cells were then treated with gemcitabine and apoptosis determined by terminal deoxynucleotidyl transferase mediated nick end labeling (TUNEL) assay. RESULTS: Chemotherapy induced NF-kappaB nuclear translocation and DNA binding in all NSCLC cell lines. H157I cells had enhanced cell death compared with H157V cells, suggesting that NF-kappaB is required for cell survival after chemotherapy. The observed cell death following the loss of NF-kappaB occurred by apoptosis. CONCLUSIONS: Inhibition of chemotherapy-induced NF-kappaB activation sensitizes NSCLC to chemotherapy-induced apoptosis in vitro. Novel treatment strategies for patients with advanced NSCLC may involve chemotherapy combined with inhibition of NF-kappaB-dependent cell-survival pathways.
BACKGROUND: Most non-small cell lung cancers (NSCLC) are chemoresistant. Identification and modulation of chemoresistance cell-signaling pathways may sensitize NSCLC to chemotherapy and improve patient outcome. The purpose of this study was to determine if chemotherapy induces nuclear factor-kappa B (NF-kappaB) activation in NSCLC in vitro and whether inhibition of NF-kappaB would sensitize tumor cells to undergo chemotherapy-induced apoptosis. METHODS:Non-small cell lung cancer cells were treated with gemcitabine, harvested, and nuclear extracts analyzed for NF-kappaB DNA binding by electrophoretic mobility shift assays. Additionally, NSCLC cells that stably expressed a plasmid encoding the superrepressor IkappaBalpha protein (H157I) or a vector control (H157V) were generated. These cells were then treated with gemcitabine and apoptosis determined by terminal deoxynucleotidyl transferase mediated nick end labeling (TUNEL) assay. RESULTS: Chemotherapy induced NF-kappaB nuclear translocation and DNA binding in all NSCLC cell lines. H157I cells had enhanced cell death compared with H157V cells, suggesting that NF-kappaB is required for cell survival after chemotherapy. The observed cell death following the loss of NF-kappaB occurred by apoptosis. CONCLUSIONS: Inhibition of chemotherapy-induced NF-kappaB activation sensitizes NSCLC to chemotherapy-induced apoptosis in vitro. Novel treatment strategies for patients with advanced NSCLC may involve chemotherapy combined with inhibition of NF-kappaB-dependent cell-survival pathways.
Authors: Yuan Liu; Marty W Mayo; Aizhen Xiao; Emily H Hall; Elianna B Amin; Kyuichi Kadota; Prasad S Adusumilli; David R Jones Journal: Mol Cell Biol Date: 2014-11-03 Impact factor: 4.272
Authors: Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell Journal: Am J Respir Cell Mol Biol Date: 2005-10-06 Impact factor: 6.914
Authors: Ngoc T Vu; Margaret A Park; Michael D Shultz; Gamze B Bulut; Amy C Ladd; Charles E Chalfant Journal: Cancer Res Date: 2016-03-29 Impact factor: 12.701
Authors: Adam Michael Clark; Steven H Reynolds; Marshall Anderson; Jonathan S Wiest Journal: Genes Chromosomes Cancer Date: 2004-10 Impact factor: 5.006
Authors: Philip W Smith; Yuan Liu; Suzanne A Siefert; Christopher A Moskaluk; Gina R Petroni; David R Jones Journal: Cancer Lett Date: 2008-12-25 Impact factor: 8.679